Online inquiry

IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13135MR)

This product GTTS-WQ13135MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13135MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4496MR IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-931699
GTTS-WQ9889MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA KB001-A
GTTS-WQ8331MR IVTScrip™ mRNA-Anti-TFRC, HN-66000(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HN-66000
GTTS-WQ6081MR IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CNTO 888
GTTS-WQ7212MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ7368MR IVTScrip™ mRNA-Anti-FZD7, FZD8-Fc(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA FZD8-Fc
GTTS-WQ15822MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA XmAb14045
GTTS-WQ10074MR IVTScrip™ mRNA-Anti-FN, L19TNF(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA L19TNF
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW